Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives $24.25 Consensus Price Target from Brokerages
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) has a consensus “Moderate Buy” rating from six covering analysts, MarketBeat reports: one sell and five buy. The average 1-year target price is $24.25. Analysts cited include HC Wainwright ($20), JonesTrading ($22), Cantor Fitzgerald (overweight), Oppenheimer ($32). ANL opened at $10.00 Monday.
How this was made
The 30-second read
Why it matters
The actionable content is the updated analyst consensus and specific target changes (HC Wainwright raised to $20; JonesTrading initiated at $22; Oppenheimer initiated at $32; Cantor initiated as overweight; one analyst upgraded to hold). This can influence short-term sentiment and positioning, but the article lacks any new company fundamentals (earnings, guidance, contracts, trials, or regulatory actions).
Market read
Traders may adjust expectations for ANL based on the consensus target ($24.25) and the mix of buy/hold ratings, but there is no new fundamental trigger in the text.
What to watch
The article includes institutional ownership changes and moving averages/52-week range, but does not connect them to a new earnings/guidance driver; traders may over-weight target revisions versus liquidity/volatility.
Background
Adlai Nortye is described as a China-based specialty chemical/fine-chemicals producer focused on amino acids and derivatives; the article frames the latest broker coverage and consensus target.
Ticker impact
Article cites a consensus “Moderate Buy” for Adlai Nortye and an average 1-year target price of $24.25, plus specific broker target changes.
Near-term bias modestly positive as traders react to target revisions; follow-through depends on whether new coverage reflects new fundamentals not provided here.
The newest concrete facts are analyst rating/price-target updates and a consensus target; no earnings, guidance, deal, or regulatory event is disclosed.
Market effects
Limited read-across: fine-chemicals/amino-acids names may see mild sentiment spillover from analyst coverage, but no sector datapoint is provided.
No direct regional macro or China-specific policy/regulatory trigger is disclosed beyond company description.
Low—this is a single-name analyst-target/coverage recap with no global supply-demand or trade shock mentioned.
Counterpoint
Analyst target dispersion is wide (e.g., $20 to $32) and the article provides no new operational metric; price may not follow targets if fundamentals haven’t changed.
Key entities
- companyAdlai Nortye Ltd. Sponsored ADR
Subject of the article; consensus “Moderate Buy” and average 1-year target price of $24.25 are reported.
- broker/analystHC Wainwright
Raised price objective from $16 to $20 and reiterated buy rating.
- broker/analystJonesTrading
Initiated coverage with buy rating and $22 price target.
- broker/analystOppenheimer
Initiated coverage with outperform rating and $32 price target.
